top of page


Bukwang Initiates Exportation of its In-House-Developed Drug, DEXIDⓇ to Southeast Asia

- Kalbe International to take on sales in 2 approved countries

Bukwang Pharmaceutical Co., Ltd (Bukwang) announced that its in-house developed drug DexidⓇ, an incrementally modified drug for the treatment of diabetic polyneuropathy, will be marketed in the first half of this year in Myanmar and Cambodia by Kalbe International (Kalbe) after having received its approval. Bukwang is also expecting the drug to be approved in the Philippines and Vietnam, which is expected to be completed by the end of this year and the start of next year, respectively.

DexidⓇ, having been marketed since early 2014, is an incrementally modified drug (IMD) developed in-house by Bukwang. Its active ingredient was isolated from ThiocacidⓇ to contain only the main active ingredient, thus improving safety and compliance of patients while maintaining efficacy.

As diabetic polyneuropathy is one of the most frequently associated complications of diabetes, Bukwang is planning to target overseas market by establishing localization strategies for each different countries- starting with Southeast Asia. Bukwang is expected to achieve over $15 million from exporting DexidⓇ to Southeast Asia 5 years after its launch in the first half of year 2020.

Bukwang, as leader of the market for diabetic polyneuropathy therapeutic products, holds both ThiocacidⓇ and DexidⓇ. Of the two, DexidⓇ, according to UBIST reports in Korea for 2019, has reached almost ₩15 billion from outpatient prescriptions and maintains its growth despite the entrance of generics into the market.

|    ​Korean    |
bottom of page